$105 Million is the total value of M28 Capital Management LP's 14 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 66.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| WVE | Sell | WAVE LIFE SCIENCES LTD | $41,323,835 | +43.4% | 5,903,405 | -26.0% | 39.39% | +30.9% |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $14,131,106 | +33.0% | 722,080 | +8.4% | 13.47% | +21.4% |
| INVIVYD INC | $13,872,375 | -52.1% | 9,248,250 | 0.0% | 13.22% | -56.2% | ||
| PRQR | Buy | PROQR THRAPEUTICS N V | $7,069,220 | +848.9% | 1,910,600 | +90.7% | 6.74% | +766.1% |
| ARWR | New | ARROWHEAD PHARMACEUTICALS IN | $5,836,584 | – | 143,900 | +100.0% | 5.56% | – |
| IONS | New | IONIS PHARMACEUTICALS INC | $4,770,351 | – | 126,300 | +100.0% | 4.55% | – |
| STOK | Sell | STOKE THERAPEUTICS INC | $4,457,075 | -33.6% | 482,890 | -7.6% | 4.25% | -39.4% |
| BBIO | Sell | BRIDGEBIO PHARMA INC | $3,192,780 | -37.4% | 419,000 | -18.4% | 3.04% | -42.9% |
| SWTX | New | SPRINGWORKS THERAPEUTICS INC | $2,858,499 | – | 109,900 | +100.0% | 2.72% | – |
| CRIS | CURIS INC | $2,465,178 | -21.4% | 4,482,142 | 0.0% | 2.35% | -28.2% | |
| SLN | New | SILENCE THERAPEUTICS PLCads | $2,224,975 | – | 145,900 | +100.0% | 2.12% | – |
| ATRA | New | ATARA BIOTHERAPEUTICS INC | $1,440,904 | – | 439,300 | +100.0% | 1.37% | – |
| TGTX | Sell | TG THERAPEUTICS INC | $1,235,052 | -38.4% | 104,400 | -69.2% | 1.18% | -43.8% |
| NEXI | NEXIMMUNE INC | $32,440 | -56.2% | 133,442 | 0.0% | 0.03% | -59.7% | |
| LPTX | Exit | LEAP THERAPEUTICS INC | $0 | – | -2,664,400 | -100.0% | -2.45% | – |
| VERV | Exit | VERVE THERAPEUTICS INC | $0 | – | -87,600 | -100.0% | -3.14% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -61,200 | -100.0% | -4.46% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-10
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| WAVE LIFE SCIENCES LTD | 8 | Q3 2023 | 46.4% |
| INVIVYD INC | 8 | Q3 2023 | 32.1% |
| ROCKET PHARMACEUTICALS INC | 8 | Q3 2023 | 16.6% |
| BRIDGEBIO PHARMA INC | 8 | Q3 2023 | 6.1% |
| TG THERAPEUTICS INC | 8 | Q3 2023 | 9.2% |
| NEXIMMUNE INC | 8 | Q3 2023 | 0.5% |
| STOKE THERAPEUTICS INC | 7 | Q2 2023 | 10.2% |
| CURIS INC | 7 | Q2 2023 | 9.7% |
| PROQR THRAPEUTICS N V | 7 | Q3 2023 | 6.7% |
| ATARA BIOTHERAPEUTICS INC | 5 | Q1 2023 | 5.6% |
View M28 Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adagio Therapeutics, Inc. | August 19, 2022 | 9,248,250 | 8.5% |
View M28 Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-12 |
| SC 13G/A | 2024-02-12 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-05-25 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-10 |
View M28 Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.